Exploring how carnosine from brain cells affects Alzheimer's disease
Official title: Development of new tools to explore the role of oligodendrocyte-derived carnosine in Alzheimer Disease
Funded at Northwestern University at Chicago · NIH-10887022 · Data updated 2026-11-12
This study is looking at how a natural substance called carnosine, made by certain brain cells, helps protect the brain from a harmful chemical linked to Alzheimer's disease, and it aims to create special mouse models to see what happens when carnosine levels are lowered.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | April 15, 2024 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $320,000 |
| NIH project number | 1R03AG087284-01 |
| Project ID | NIH-10887022 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for Alzheimer's disease or those in the early stages of cognitive decline.
✕Less likely to help
Patients with advanced Alzheimer's disease or those without any cognitive impairment may not benefit from this research.
What this research studies
This research investigates the role of carnosine, a compound produced by specific brain cells called oligodendrocytes, in detoxifying a harmful substance known as acrolein, which is linked to Alzheimer's disease. The study aims to develop genetic mouse models to reduce carnosine levels in the brain, allowing researchers to better understand its impact on aging and the development of Alzheimer's. By examining these models, the research seeks to uncover the mechanisms by which carnosine may protect against the toxic effects of acrolein in the context of Alzheimer's disease.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance carnosine levels in the brain, potentially slowing or preventing the progression of Alzheimer's disease.
How similar studies have gone: Previous studies have shown promising results in using carnosine supplementation to improve brain function in aging models, suggesting that this approach may hold potential for Alzheimer's treatment.
Where this research is happening
-
Northwestern University at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Elbaz-Eilon, Benayahu — Northwestern University at Chicago
- Study coordinator: Elbaz-Eilon, Benayahu
Related research
Other NIH-funded projects on the same topics.
-
Mitochondrial energy problems in men and women with Alzheimer’s disease
This grant tests how mitochondria differ between men and women with Alzheimer's disease to find ways to tailor care.
-
Mitochondrial energy problems in people with Alzheimer’s and related brain diseases
A research effort is looking at how mitochondrial energy problems differ between men and women with Alzheimer’s disease and related dementias and what this means for future care.
-
Understanding Alzheimer's Genetic Risk in African and Admixed African-American People
A study looks at genetic factors and biomarkers to understand why Alzheimer's disease affects African and admixed African-American communities differently.
-
Genetic Risk for Alzheimer’s in African and admixed African-American communities
Researchers will study how genes influence Alzheimer’s risk in people of African ancestry to better understand why the disease affects diverse communities differently.
-
Genetic Risk for Alzheimer’s Disease in African and African-American Ancestries
Researchers are studying how genes influence Alzheimer’s risk in people of African and mixed African-American backgrounds to improve understanding and prevention.
-
Understanding genetic risk for Alzheimer’s in African and admixed African-American communities
Researchers are studying how genetic factors influence Alzheimer’s risk in people of African ancestry to better understand why dementia affects these groups differently.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.